D. D. Korostovtsev
D. D. Korostovtsev has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- A. V. Yatsenko
EpiJay Clinic of Neurology and Epileptology
2 shared publications - Elena V. Gumennik
EpiJay Clinic of Neurology and Epileptology
2 shared publications - Marina Kovelenova
Clinic of Neurology and Epileptology “Epidzhey
2 shared publications - Yu.A. Yakovleva
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology
2 shared publications - A. V. Markin
Svt. Luka’s Institute of Child and Adult Neurology and Epilepsy
1 shared publication - Dmitriy Yu. Butko
Saint Petersburg State Pediatric Medical University
1 shared publication
Latest Publications
- Open Access
- 30 April 2026
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 21 (1)
Threshold analysis of the patient’s route in infantile epileptic spasms syndrome: from the onset of spasms to first-line therapy
Background. Infantile epileptic spasms syndrome (IESS) is one of the most severe forms of early-onset epileptic encephalopathies and is associated with a high risk of pharmacoresistance, severe cognitive impairment, and premature mortality. Disease prognosis critically depends on the timeliness and adequacy of first-line therapy. Although delayed treatment of IESS is a universal problem, the specific stages of the patient care pathway at which delays occur may vary substantially depending on the organization of healthcare delivery. Aim. To identify key threshold stages of the patient care pathway and major barriers to timely initiation of rational therapy in children with IESS within the healthcare system of Saint Petersburg. Materials and methods. A retrospective observational study was conducted using the archive of the Epilepsy Clinic since 2018. A total of 130 children diagnosed with IESS according to International League Against Epilepsy criteria were included. Clinical and anamnestic data, magnetic resonance imaging findings, electroencephalography/video-electroencephalography monitoring results, and genetic testing data were analyzed. A threshold analysis of six consecutive stages of the patient care pathway was performed, from initial recognition of spasms to prescription of appropriate first-line therapy regimens. Early treatment response was assessed 2 weeks after therapy initiation Results. Developmental abnormalities prior to epileptic spasms onset were identified in 78 % of children; potentially epileptogenic magnetic resonance imaging abnormalities were found in 67 %. Causative genetic variants were detected in 18 % of the entire cohort. In 39 % of patients, the diagnosis was not established within the first month after spasm onset. In 96 (74 %) of 130 children, rational therapy was initiated more than one month after spasm onset. Six threshold points of potential treatment delay were identified. The main point of patient loss was late recognition of spasms at the stage of initial medical contact (loss of 27 out of 130 children). Moreover, delay at this stage deprived the child of any chance to receive timely therapy and constituted an insurmountable barrier to the subsequent steps of care. The second most important barrier was failure to initiate appropriate first-line therapy at treatment onset. The effectiveness of first-line therapy was more than 12-fold higher than that of standard antiseizure medications. Conclusion. Timely initiation of rational therapy in IESS is the result of passing through several consecutive threshold stages of the patient care pathway. The key systemic barriers in Saint Petersburg are late recognition of epileptic spasms and insufficient implementation of first-line therapy. These findings highlight the necessity of analyzing patient pathways within specific healthcare models and developing targeted programs for early detection and optimization of initial treatment.
- 30 April 2026
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 21 (1)
Open AccessThreshold analysis of the patient’s route in infantile epileptic spasms syndrome: from the onset of spasms to first-line therapy
Background. Infantile epileptic spasms syndrome (IESS) is one of the most severe forms of early-onset epileptic encephalopathies and is associated with a high risk of pharmacoresistance, severe cognitive impairment, and premature mortality. Disease prognosis critically depends on the timeliness and adequacy of first-line therapy. Although delayed treatment of IESS is a universal problem, the specific stages of the patient care pathway at which delays occur may vary substantially depending on the organization of healthcare delivery. Aim. To identify key threshold stages of the patient care pathway and major barriers to timely initiation of rational therapy in children with IESS within the healthcare system of Saint Petersburg. Materials and methods. A retrospective observational study was conducted using the archive of the Epilepsy Clinic since 2018. A total of 130 children diagnosed with IESS according to International League Against Epilepsy criteria were included. Clinical and anamnestic data, magnetic resonance imaging findings, electroencephalography/video-electroencephalography monitoring results, and genetic testing data were analyzed. A threshold analysis of six consecutive stages of the patient care pathway was performed, from initial recognition of spasms to prescription of appropriate first-line therapy regimens. Early treatment response was assessed 2 weeks after therapy initiation Results. Developmental abnormalities prior to epileptic spasms onset were identified in 78 % of children; potentially epileptogenic magnetic resonance imaging abnormalities were found in 67 %. Causative genetic variants were detected in 18 % of the entire cohort. In 39 % of patients, the diagnosis was not established within the first month after spasm onset. In 96 (74 %) of 130 children, rational therapy was initiated more than one month after spasm onset. Six threshold points of potential treatment delay were identified. The main point of patient loss was late recognition of spasms at the stage of initial medical contact (loss of 27 out of 130 children). Moreover, delay at this stage deprived the child of any chance to receive timely therapy and constituted an insurmountable barrier to the subsequent steps of care. The second most important barrier was failure to initiate appropriate first-line therapy at treatment onset. The effectiveness of first-line therapy was more than 12-fold higher than that of standard antiseizure medications. Conclusion. Timely initiation of rational therapy in IESS is the result of passing through several consecutive threshold stages of the patient care pathway. The key systemic barriers in Saint Petersburg are late recognition of epileptic spasms and insufficient implementation of first-line therapy. These findings highlight the necessity of analyzing patient pathways within specific healthcare models and developing targeted programs for early detection and optimization of initial treatment.
- 30 December 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (12) , 178-187
Cognitive effects of perampanel assessed by the EpiTrack Junior Test in school-aged children with epilepsy
Objective. To evaluate the impact of add-on perampanel on cognitive functions in school-aged children with epilepsy using the EpiTrack Junior test. Material and methods. Seventy-five patients aged 6—18 years were assessed before and 2 months after reaching a stable perampanel dose. They are divided into 2 groups according to the inclusion period (before 2023 and after 2023) due to the emergence of new literature data on the drug’s specific effectiveness in early adjuvant therapy after 2023. The 1st retrospective group consisted of 49 patients, most of whom were prescribed perampanel as a 4th—6th drug (54%). The 2nd prospective group consisted of 26 patients, most of whom (65%) were prescribed perampanel as a 2nd—3rd drug. Changes in total and subtest scores were analyzed versus diagnosis, sex, seizure-onset age, pharmacoresistance and EEG. Results. 66 patients completed the study. A significant increase in total EpiTrack score was observed (p<0.05) with positive correlation to seizure-onset age. Seizure reduction ≥50 % occurred in 68% and EEG improved in 40.9%. Reversible adverse events were reported in 25.8%. No statistically significant differences were found between the groups for any of these factors Conclusion. Adjunctive perampanel improves executive functions and is well tolerated in school-aged children with epilepsy.
- 30 December 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (12) , 178-187
Cognitive effects of perampanel assessed by the EpiTrack Junior Test in school-aged children with epilepsy
Objective. To evaluate the impact of add-on perampanel on cognitive functions in school-aged children with epilepsy using the EpiTrack Junior test. Material and methods. Seventy-five patients aged 6—18 years were assessed before and 2 months after reaching a stable perampanel dose. They are divided into 2 groups according to the inclusion period (before 2023 and after 2023) due to the emergence of new literature data on the drug’s specific effectiveness in early adjuvant therapy after 2023. The 1st retrospective group consisted of 49 patients, most of whom were prescribed perampanel as a 4th—6th drug (54%). The 2nd prospective group consisted of 26 patients, most of whom (65%) were prescribed perampanel as a 2nd—3rd drug. Changes in total and subtest scores were analyzed versus diagnosis, sex, seizure-onset age, pharmacoresistance and EEG. Results. 66 patients completed the study. A significant increase in total EpiTrack score was observed (p<0.05) with positive correlation to seizure-onset age. Seizure reduction ≥50 % occurred in 68% and EEG improved in 40.9%. Reversible adverse events were reported in 25.8%. No statistically significant differences were found between the groups for any of these factors Conclusion. Adjunctive perampanel improves executive functions and is well tolerated in school-aged children with epilepsy.